1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
68A3A501C346CB14385257FED005D60AE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-role-medical-affairs-payer-interactions-partnerships-field-resources-structure
18
19
2054.174.51.80
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Health Outcomes

The Role of Medical Affairs in Payer Interactions: Partnerships, Field Resources, and Structure

ID: 5421


Features:

13 Info Graphics

15 Data Graphics

170+ Metrics

3 Narratives


Pages/Slides: 36


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "The Role of Medical Affairs in Payer Interactions: Partnerships, Field Resources, and Structure"

STUDY OVERVIEW

With payers wielding so much influence on formulary access, pharmaceutical companies understand the importance of providing accurate and compelling health outcomes information to the payer community. And with the medical affairs function already involved in the dissemination of medical information, many pharma companies have turned to this function to aid in critical payer interactions.

However, medical affairs organizations often face challenges in the planning and management of payer engagement and market access activities.

Best Practices, LLC undertook this benchmarking study to understand the role of medical affairs in critical payer interactions and to highlight strategies for building and maintaining effective relationships with payers. This study provides benchmarks around preferred payer interactions, field staff access and interaction frequency and medical affairs structure.

This study includes segments for large and small companies and US only and global.


KEY TOPICS

  • Capturing Payer Insights and Partnerships with Payers
  • Field Resources for Payers
  • Medical Affairs Leadership and Structure

KEY METRICS
  • Critical elements of strong payer communications
  • Role of Medical Affairs professionals in carrying out activities designed to probe payer needs and perspectives
  • Success factors for strong payer teams
  • Number of projects or studies to be conducted by Medical Affairs organizations in collaboration with payers by the end of this year
  • Effectiveness of payer and market access services at different product lifecycle stages
  • Critical factors for payers in partnership decisions
  • Type of field-based resources deployed by Medical Affairs organization to support payers
  • Market access and payer activities staffing trends
  • Frequency of access to payer or market access organizations
  • Impact of product portfolio diversity on Medical Affairs groups’ access to key payers
  • Current structure of participants’ Medical Affairs organization
  • Leadership for thought leader management
SAMPLE KEY FINDINGS

Effectiveness of Services in Product Lifecycle: It is critical for Medical Affairs groups to adjust to the needs of payers during every stage of the product lifecycle.

  • During pre-launch, it’s key to understand the payer needs via in-person meetings and advisory boards.
  • During launch, it’s important to convey clinical findings to payers.
  • After launch, the focus is on real world and health outcomes data.
METHODOLOGY

This study reflects the data of 29 survey responses from Medical Affairs leaders at 27 biopharmaceutical companies.

Industries Profiled:
Pharmaceutical; Biopharmaceutical; Biotech; Manufacturing; Chemical; Health Care


Companies Profiled:
Abbvie; Alkermes; AstraZeneca; Baxalta; Biogen; CSL Behring; Daiichi Sankyo; EMD Serono; Genentech; Genomic Health; Lundbeck; Incyte; Janssen; Medivation; Mesoblast; Novartis; Pacira Pharmaceuticals; Pfizer; Pharmacyclics; ProStrakan; Santen; Servier; Shire; Teva Pharmaceutical Industries Ltd; Upsher-Smith; ViiV Healthcare


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.